Mar 27, 2024
- Mar 26, 2025

CAR T Research and Treatment Advances in Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL) and Follicular Cell Lymphoma (FL) Therapies

EARNed Credits

1.0

AMA PRA Category 1 CreditTM

iStock-1420501751-scaled

Overview

This CME program will highlight recent advances in the treatment and management of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and follicular cell lymphoma (FL). The expert faculty, led by Jeremy S. Abramson, MD, will first provide an update on CAR T cell therapies in 2024, including a summary of current approvals in the lymphoma treatment landscape. Following, recent trial data, including patient selection and sequencing, for CLL, MCL and FL therapeutics will be reviewed, along with the implications for clinical practice. The expert faculty will conclude with a case-based discussion of best practices for the treatment and management of patients with lymphomas to improve outcomes and quality of life.

Who Should Attend

Hematologists, academic oncologists, community oncologists, managed care oncologists, APPs, oncology pharmacists, and other healthcare providers who care for patients with lymphomas

Provided By

Course Faculty

Jeremy Abramson, MD
Director, Jon and Jo Ann Hagler Center for Lymphoma Massachusetts General Hospital Cancer Center Associate Professor of Medicine, Harvard Medical School Boston, Massachusetts
J. Erika Haydu, MD, PhD
Massachusetts General Hospital Cancer Center Instructor in Medicine, Harvard Medical School Boston, Massachusetts
James Weitzman, MD
Mass General West and Emerson Hospital Massachusetts General Hospital Cancer Center Boston, Massachusetts

Learning Objectives

1

Healthcare providers should review and be able to analyze and contextualize clinical trial data for CAR T cell therapy to manage patients with CLL, FL and MCL released at ASCO 2023, ICML 2023, and ASH 2023

2

Healthcare providers should be able to choose and position CAR T cell therapy to treat CLL, guided by clinical trial findings optimizing mechanism of action, sequencing of therapy, and patient selection

3

Healthcare providers should review and be able to analyze and contextualize clinical trial data for CAR T cell therapy to manage patients with mantle cell lymphoma, including data released at ICML 2023 and ASH 2023

4

Healthcare providers should review and be able to analyze and contextualize clinical trial data for CAR T cell therapy to manage patients with follicular cell lymphoma, including data released at ICML 2023 and ASH 2023

5

Healthcare providers in varied practice settings should have the opportunity to critically evaluate and consider incorporation of practice patterns from outside their experience in the management of patients with lymphomas

Course Agenda

1

CAR T-Cell Therapy 2023 Clinical Trials and FDA Approval Update

2

New Data-Informed Patient Selection and Sequencing of CLL Therapy

3

New Data-Informed Patient Selection and Sequencing of MCL Therapy

4

New Data-Informed Patient Selection and Sequencing of FL Therapy

5

Panel Discussion: Finding Common Ground for Best Practice

Additional Course Information

It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
Jeremy Abramson, MD

 

Consultant/Advisor: AbbVie Inc.; Bristol Myers Squibb Company; Cellectar BioSciences; Lilly; Genentech, Inc.; Gilead Sciences, Inc.; Interius BioTherapeutics, Inc.; Seagen;Grant/Research Support: Bristol Myers Squibb Company; Cellectis; Merck & Co., Inc.; Mustang Bio; Seagen; Tempus
J. Erika Haydu, MD, PhD Consultant/Advisor: GeneMag Pharmaceuticals
James Weitzman, MD

 

Consultant/Advisor: AbbVie Inc.; Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc; Novartis AG

Timothy Hayes, MD, PhD; Charles V. Pollack Jr., MD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Simonds hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.

Physcians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been supported by an independent educational grant from Bristol Myers Squibb Company.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Bristol Myers Squibb Company do not recommend the use of any agent outside of the labeled indications.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

For all CE inquiries or special needs, please contact [email protected].

Mar 27, 2024
- Mar 26, 2025

CAR T Research and Treatment Advances in Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL) and Follicular Cell Lymphoma (FL) Therapies

Related Webcast Courses

Oncology
The Advancing Role of PARP Inhibitor Combination Therapies to Improve Outcomes for Patient...
Oncology
Utilizing Immunohistochemistry Testing, Biomarkers, and Targeted Therapeutics to Optimize ...
Oncology
Applying Poly (ADP-ribose) Polymerase (PARP) Inhibitors to Maintenance Treatment Plans to ...